Objective: To explore the protective or influence effect of Bifidobacterium (BIFI) on liver function of chronic alcoholic liver injury (CALI) rats, and to preliminarily explore its mechanism.
Methods: SD rats were randomly divided into CALI group, metadoxine (90mg/kg) group, low BIFI (500 mg/kg), medium (1000 mg/kg) and high (2000 mg/kg) dose group. Silent information regulatory protein 1 (silent information regulatory protein SIRT1) inhibitor Tenovin-6 (25mg/kg) group. CALI group and blank control group were given an equal volume of normal saline intragastrically. After 8 weeks, the liver function of each group was analyzed; Detection of TG and TC levels in liver tissue and serum; hematoxylin-eosin (HE) staining to observe liver tissue pathological changes; Western blot (WB) method to analyze the expression of SIRT1 and chREBP in liver tissue.
Results: Compared with the control group, the liver function of the rats in the CALI group was significantly decreased, the ALT and AST levels in the blood were significantly increased (P<0.05), the liver tissue showed fatty pathological damage, and the levels of TG and TC in the liver tissue and serum were significantly increased. High (P<0.05), the expression of SIRT1 protein was significantly reduced (P<0.05), and the expression of chREBP protein was significantly increased (P<0.05); compared with the CALI group, the BIFI low, medium, and high-dose group of rats CALI group rat liver function Significantly enhanced, blood ALT and AST levels were significantly reduced (P<0.05), liver tissue pathological damage was significantly reduced, TG and TC levels in liver tissue and serum were significantly reduced (P<0.05), and SIRT1 protein expression was significantly increased (P<0.05) 0.05), chREBP protein expression was significantly reduced (P <0.05). The above effects can be reversed by the SIRT1 specific inhibitor Tenovin-6.
Conclusion: BIFI may inhibit lipid accumulation by regulating the expression of SIRT1/ChREBP, and protect rats with chronic alcoholic liver injury.